HIV pre-exposure prophylaxis in injecting drug users

The Lancet

Volumn 381, Issue 9883, 2013, Pages 2060-2062

  Abdool Karim, Salim S ^a,b  

^a UNIVERSITY OF KWAZULU NATAL   (South Africa)

^b Columbia University ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TENOFOVIR;

DRUG EFFICACY; FOLLOW UP; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTRAVENOUS DRUG ABUSE; NONHUMAN; NOTE; PRIORITY JOURNAL; PROPHYLAXIS;

EID: 84878977681     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(13)61140-X     Document Type: Note

References (6)

1. Mathers BM, Degenhardt L, Phillips B, et al. Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review. Lancet 2008; 372: 1733-45.
2. Sendziuk P. Harm reduction and HIV-prevention among injecting drug users in Australia: an international comparison. Can Bull Med Hist 2007; 24: 113-29.
3. UNAIDS. HIV prevention among injecting drug users. http://data.unaids. org/pub/InformationNote/2009/20090518-hiv-prevention-among-idus-final-en.pdf (accessed June 4, 2013).
4. Mofenson LM. Short-course zidovudine for prevention of perinatal infection. Lancet 1999; 353: 766-67.
5. Abdool Karim SS, Abdool Karim Q. Antiretroviral prophylaxis: a defi ning moment in HIV control. Lancet 2011; 378: e23-25.
6. Choopanya K, Martin M, Suntharasamai, et al, for the Bangkok Tenofovir Study Group. Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo controlled phase 3 trial. Lancet 2013; published online June 13. http://dx.doi.org/10.1016/S0140-6736(13)61127-7.